Clinical Trials Browser

INDUSTRY × Carcinoma, Renal Cell × 30 days × Clear all

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07419841 2026-06-05

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Phase 1 Recruiting

70 enrolled

GastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Endometrial Neoplasms

NCT04458259 2026-06-04

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Phase 1 Terminated

88 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma

NCT04777994 2026-06-04

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Phase 1 Recruiting

248 enrolled

GenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Recurrence

NCT04895709 2026-06-04

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

1,109 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

ARC-25

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Study of PF-07265807 in Participants With Metastatic Solid Tumors.

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

LITESPARK-033

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

BASECAMP-1

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

CABOCARE

REPLICA

ARC-20

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

DP-04

89Zr-DFO-girentuximab Expanded Access Program (EAP)

MK-6482-043

LITESPARK-034

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

STARTRK-2

STELLAR-002

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

MK-3475-03C

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

MK-6482-018

SAMETA

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

DESCENT-1

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

MK-3475-03A

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma

Keynote B59

MK-6482-022

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors